Shire Canada Inc. ("Shire Canada") and Shire Human Genetic Therapies (Canada)
Inc. ("Shire Human Genetic Therapies (Canada)") are wholly owned subsidiaries of
Shire plc, a global specialty biopharmaceutical company that works closely with
specialist physicians to develop and market medicines that improve the quality
of life for patients, their families and caregivers.
Shire focuses on attention deficit hyperactivity disorder (ADHD), human genetic
therapies, hereditary angioedema, as well as gastrointestinal and renal
In Canada, Shire is a proud member of Canada's Research-Based Pharmaceutical
Companies (Rx&D) and of BIOTECanada.
Our Canadian offices are located in the Greater Montreal area, in Québec:
2250 Alfred-Nobel Blvd, Suite 500
Saint-Laurent, QC H4S 2C9
Tel: +1 514 787 2300
Fax: +1 514 787 2427